What’s Next for Eli Lilly Alzheimer’s Drug Donanemab? Trial Enrollment Continues

We talked with Banner Alzheimer’s Institute Director Pierre Tariot about the most recent results from Eli Lilly’s Alzheimer’s trial for donanemab — what he…